Charles River Acquires ChanTest
News Oct 31, 2014
Headquartered in Cleveland, Ohio, ChanTest offers a panel of more than 120 validated assays to test ion channels, which we believe is the most comprehensive panel in the industry. ChanTest scientists are thought leaders in the field of ion channels and are currently working with the FDA on the Comprehensive in vitro Proarrhythmia Assay (CiPA) guidelines.
As researchers increasingly incorporate ion channel testing into their molecule design process, access to more comprehensive ion channel assay panels will be invaluable to supporting their drug discovery efforts. With this acquisition, we are emerging as the market-leading CRO in ion channel drug discovery and associated in vitro safety testing.
Discovery Provides Hope for New Vaccine Against Flesh-eating BacteriaNews
Researchers at Houston Methodist have solved a 100-year-old mystery, providing them a possible key to unlock a pathway for treating diseases caused by flesh-eating bacteria.READ MORE
Hits for a Novel Drug Target Identified for Depression and PainNews
Novel small molecules have been identified that might be transformed into a new medical treatment of depression and/or even the potential in the treatment of pain.READ MORE
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE